Skip to Content
IRS Whistleblowers, click here to contact the Ways & Means Committee about waste, fraud, and abuse.

Hern: Dems’ Drug Price Controls Will Makes it Harder for Americans to Access Life-Saving Drugs

August 25, 2022 — Blog    — Health    — Op-eds and Speeches    — Press Releases   

Patients with insulin will face higher prices and lower quality care as a result of Democrats’ socialized drug price controls, Ways and Means Republican Rep. Kevin Hern (R-OK) writes in an op-ed for the Daily Signal. 


CLICK HERE to read the full op-ed.


Key Excerpts:

  • “If Democrats have their way, new regulations will make it harder for Americans to access life-saving pharmaceuticals such as insulin.”


  • “In reality, price controls would be detrimental to patients who need insulin. Studies show that government price controls and overburdensome regulations in pharmaceuticals have resulted in increased prices, lower quality care, and longer wait times.”


  • “These regulations and price controls almost always result in higher health insurance premiums. In fact, one study found that premiums for plans that cap insulin cost double those that don’t.”


  • “As is typical with Democrats, they’re not waiting to see how these newly approved drugs bring down costs. They’re trying to use the government to solve a government-created problem and introduce socialist price controls to cap the price of insulin, passing the extra costs back onto taxpayers in the form of higher premiums.”


CLICK HERE to read the full op-ed.


READ: Dems’ Drug Pricing Scheme Increases Costs, CBO Confirms


Key Background:

Democrats’ socialist drug pricing scheme will raise prices on new drugs.

  • Higher launch prices for prescription drugs will increase costs at the pharmacy counter and raise insurance premiums, pushing new cures out of reach for most American patients except the wealthiest.
  • The policy remaining in Democrats’ so-called “Inflation Reduction Act” institutes a $35 cap on monthly cost sharing for insulin prices for people in Medicare. This policy spends an estimated additional $6 billion, further reducing the claimed “deficit reductions,” while doing nothing to expand supply or reduce high prices.


The vast majority of Americans oppose government negotiation if it results in fewer new medicines being developed in the future.

  • A 50-state Morning Consult/PhRMA poll shows two thirds of Americans oppose price controls if they put the government in charge and take away power from doctors to prescribe medicines that best meet the needs of patients.